H. Lundbeck A/S has appointed Ole Vahlgren, a member of its corporate management group, to the position of senior vice president for corporate business development and strategy. He will report to the company’s chief executive officer, Ulf Wiinberg. A Lundbeck executive since 1993, Mr Vahlgren has been responsible for augmenting the company’s internal research through partnerships and acquisitions. He played a role in establishing Lundbeck’s partnership with Mochida Pharmaceutical Co Ltd for the development of the antidepressant, escitalopram, as well as the in-licensing of desmoteplase for stroke. He also helped manage Lundbeck’s 2009 acquisition of Ovation Pharmaceuticals Inc of the US. Mr Vahlgren holds degrees in civil engineering and in business administration.
Copyright 2010 Evernow Publishing Ltd